- Vouliez-vous dire
- mechanisms
Résultats de la recherche - 2 results
Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.
mechanical ventilation on Day 15 was not different between both groups (convalescent plasma: 83.74% (n=267) control: 84.05% (n=137) — Odds ratio 0.99 (0.59-1.66) — p-value=0.9772). The intervention did not ...
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the DAWn-Plasma trial.
483 patients and will recruit from 25 centres across Belgium. The primary endpoint is the proportion of patients that require mechanical ventilation or have died at day 15. The main secondary endpoints ...